Chapter 5. Case Study on Definition of Process Design Space for a Microbial Fermentation Step
- Anurag S. Rathore1,
- Rohin Mhatre2
Published Online: 28 OCT 2008
DOI: 10.1002/9780470466315.ch5
Copyright © 2009 John Wiley & Sons, Inc.
Book Title

Quality by Design for Biopharmaceuticals: Principles and Case Studies
Additional Information
How to Cite
van Hoek, P., Harms, J., Wang, X. and Rathore, A. S. (2008) Case Study on Definition of Process Design Space for a Microbial Fermentation Step, in Quality by Design for Biopharmaceuticals: Principles and Case Studies (eds A. S. Rathore and R. Mhatre), John Wiley & Sons, Inc., Hoboken, NJ, USA. doi: 10.1002/9780470466315.ch5
Editor Information
- 1
Amgen Inc., Thousand Oaks, California, USA
- 2
Biogen Idec, Cambridge, Massachusetts, USA
Publication History
- Published Online: 28 OCT 2008
- Published Print: 8 JUN 2009
ISBN Information
Print ISBN: 9780470282335
Online ISBN: 9780470466315
- Summary
- Chapter
- References
Keywords:
- concept of “design space” in biotech community;
- FMEA risk assessment tool in biotech industry for underlying rigorous methodology;
- characterization ranges (CRs) and normal operating range (NOR)
Summary
This chapter contains sections titled:
Introduction
Approach Toward Process Characterization
Risk Analysis
Small-Scale Model Development and Qualification
Design of Experiment Studies
Worst Case Studies
Definition of Design Space
Definition of Validation Acceptance Limits
Regulatory Filing, Process Monitoring, and Postapproval Changes
Acknowledgment
References
